These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 36905103)

  • 1. Prognostic-Related Biomarkers in Pancreatic Ductal Adenocarcinoma Correlating with Immune Infiltrates Based on Proteomics.
    Kou YQ; Yang YP; Pan ZJ; Du SS; Yuan WN; He K; Nie B
    Med Sci Monit; 2023 Mar; 29():e938785. PubMed ID: 36905103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma.
    Zhang Y; Xu J; Hua J; Liu J; Liang C; Meng Q; Wei M; Zhang B; Yu X; Shi S
    J Immunother Cancer; 2019 Aug; 7(1):233. PubMed ID: 31464648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Analysis of Expression, Prognostic Value, and Immune Infiltration for Ubiquitination-Related FBXOs in Pancreatic Ductal Adenocarcinoma.
    Zhang Y; Liu Q; Cui M; Wang M; Hua S; Gao J; Liao Q
    Front Immunol; 2021; 12():774435. PubMed ID: 35046938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A protein-based prognostic model for pancreatic ductal adenocarcinoma: Construction and validation.
    Xu Y; Wang Y; Chen Q; Yao T; Qiu J; Ni L; Chen H; Liang T
    Pancreatology; 2023 Dec; 23(8):1003-1013. PubMed ID: 37923686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune cell infiltrates as prognostic biomarkers in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.
    McGuigan AJ; Coleman HG; McCain RS; Kelly PJ; Johnston DI; Taylor MA; Turkington RC
    J Pathol Clin Res; 2021 Mar; 7(2):99-112. PubMed ID: 33481339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of Proteomics in Pancreatic Ductal Adenocarcinoma Biomarker Investigations: A Review.
    Vellan CJ; Jayapalan JJ; Yoong BK; Abdul-Aziz A; Mat-Junit S; Subramanian P
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
    Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
    Front Immunol; 2021; 12():648917. PubMed ID: 33777046
    [No Abstract]   [Full Text] [Related]  

  • 8. Identification of novel genes associated with a poor prognosis in pancreatic ductal adenocarcinoma via a bioinformatics analysis.
    Zhou J; Hui X; Mao Y; Fan L
    Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31311829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of the transcriptional expressions and prognostic value of S100A family in pancreatic ductal adenocarcinoma.
    Li HB; Wang JL; Jin XD; Zhao L; Ye HL; Kuang YB; Ma Y; Jiang XY; Yu ZY
    BMC Cancer; 2021 Sep; 21(1):1039. PubMed ID: 34530774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathological features related to onco-immunity and their clinical significance of pancreatic ductal adenocarcinoma].
    Wang CM; Xu CY; Jiang S; Zhou Q; Jiang ZJ; Cheng GP; Wu MJ; Feng TT; Yin WJ
    Zhonghua Bing Li Xue Za Zhi; 2022 May; 51(5):419-424. PubMed ID: 35511637
    [No Abstract]   [Full Text] [Related]  

  • 11. N6-methylandenosine-related lncRNAs play an important role in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma.
    Hu Y; Chen Y
    Sci Rep; 2021 Sep; 11(1):17844. PubMed ID: 34497315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of kallikrein-related peptidase 7 predicts poor prognosis in patients with unresectable pancreatic ductal adenocarcinoma.
    Iakovlev V; Siegel ER; Tsao MS; Haun RS
    Cancer Epidemiol Biomarkers Prev; 2012 Jul; 21(7):1135-42. PubMed ID: 22573795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arpin downregulation is associated with poor prognosis in pancreatic ductal adenocarcinoma.
    Zhang SR; Li H; Wang WQ; Jin W; Xu JZ; Xu HX; Wu CT; Gao HL; Li S; Li TJ; Zhang WH; Xu SS; Ni QX; Yu XJ; Liu L
    Eur J Surg Oncol; 2019 May; 45(5):769-775. PubMed ID: 30416079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of astrocyte elevated gene-1 (AEG-1) as a biomarker for aggressive pancreatic ductal adenocarcinoma.
    Huang Y; Ren GP; Xu C; Dong SF; Wang Y; Gan Y; Zhu L; Feng TY
    BMC Cancer; 2014 Jul; 14():479. PubMed ID: 24989027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl peptidase like 6 promoter methylation is a potential prognostic biomarker for pancreatic ductal adenocarcinoma.
    Zhao X; Cao D; Ren Z; Liu Z; Lv S; Zhu J; Li L; Lang R; He Q
    Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32701143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic features and prognostic implications of MYBL2 protein expression in pancreatic ductal adenocarcinoma.
    Yu R; Li C; Lin X; Chen Q; Li J; Song L; Lin L; Liu J; Zhang Y; Kong W; Ouyang X; Chen X
    Pathol Res Pract; 2017 Aug; 213(8):964-968. PubMed ID: 28559119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic identification of potential prognostic biomarkers in resectable pancreatic ductal adenocarcinoma.
    Iuga C; Seicean A; Iancu C; Buiga R; Sappa PK; Völker U; Hammer E
    Proteomics; 2014 Apr; 14(7-8):945-55. PubMed ID: 24459066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
    Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
    J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.